Your browser doesn't support javascript.
loading
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.
Taylor, Jenny C; Martin, Hilary C; Lise, Stefano; Broxholme, John; Cazier, Jean-Baptiste; Rimmer, Andy; Kanapin, Alexander; Lunter, Gerton; Fiddy, Simon; Allan, Chris; Aricescu, A Radu; Attar, Moustafa; Babbs, Christian; Becq, Jennifer; Beeson, David; Bento, Celeste; Bignell, Patricia; Blair, Edward; Buckle, Veronica J; Bull, Katherine; Cais, Ondrej; Cario, Holger; Chapel, Helen; Copley, Richard R; Cornall, Richard; Craft, Jude; Dahan, Karin; Davenport, Emma E; Dendrou, Calliope; Devuyst, Olivier; Fenwick, Aimée L; Flint, Jonathan; Fugger, Lars; Gilbert, Rodney D; Goriely, Anne; Green, Angie; Greger, Ingo H; Grocock, Russell; Gruszczyk, Anja V; Hastings, Robert; Hatton, Edouard; Higgs, Doug; Hill, Adrian; Holmes, Chris; Howard, Malcolm; Hughes, Linda; Humburg, Peter; Johnson, David; Karpe, Fredrik; Kingsbury, Zoya.
Afiliação
  • Taylor JC; NIHR Comprehensive Biomedical Research Centre, Oxford, UK.
  • Martin HC; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Lise S; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Broxholme J; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Cazier JB; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Rimmer A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Kanapin A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Lunter G; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Fiddy S; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Allan C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Aricescu AR; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Attar M; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Babbs C; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Becq J; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Beeson D; Illumina Cambridge Limited, Saffron Walden, UK.
  • Bento C; Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Bignell P; Hematology Department, Centro Hospitalar e Universitário de Coimbra, Portugal.
  • Blair E; Molecular Haematology Department, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Buckle VJ; Department of Clinical Genetics, Oxford University Hospitals NHS Trust, Oxford, UK.
  • Bull K; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Cais O; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Cario H; Centre for Cellular and Molecular Physiology, University of Oxford, Oxford, UK.
  • Chapel H; Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK.
  • Copley RR; Department of Pediatrics and Adolescent Medicine, University Medical Center, Ulm, Germany.
  • Cornall R; Primary Immunodeficiency Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Craft J; NIHR Comprehensive Biomedical Research Centre, Oxford, UK.
  • Dahan K; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Davenport EE; Centre for Cellular and Molecular Physiology, University of Oxford, Oxford, UK.
  • Dendrou C; NIHR Comprehensive Biomedical Research Centre, Oxford, UK.
  • Devuyst O; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Fenwick AL; Centre de Génétique Humaine, Institut de Génétique et de Pathologie, Gosselies, Belgium.
  • Flint J; Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Fugger L; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Gilbert RD; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Goriely A; Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
  • Green A; Clinical Genetics Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Greger IH; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Grocock R; MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Gruszczyk AV; University Hospital Southampton NHS Foundation Trust, University of Southampton, Southampton, UK.
  • Hastings R; Clinical Genetics Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Hatton E; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Higgs D; Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK.
  • Hill A; Illumina Cambridge Limited, Saffron Walden, UK.
  • Holmes C; Clinical Genetics Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Howard M; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Hughes L; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Humburg P; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Johnson D; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Karpe F; The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Kingsbury Z; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
Nat Genet ; 47(7): 717-726, 2015 Jul.
Article em En | MEDLINE | ID: mdl-25985138
ABSTRACT
To assess factors influencing the success of whole-genome sequencing for mainstream clinical diagnosis, we sequenced 217 individuals from 156 independent cases or families across a broad spectrum of disorders in whom previous screening had identified no pathogenic variants. We quantified the number of candidate variants identified using different strategies for variant calling, filtering, annotation and prioritization. We found that jointly calling variants across samples, filtering against both local and external databases, deploying multiple annotation tools and using familial transmission above biological plausibility contributed to accuracy. Overall, we identified disease-causing variants in 21% of cases, with the proportion increasing to 34% (23/68) for mendelian disorders and 57% (8/14) in family trios. We also discovered 32 potentially clinically actionable variants in 18 genes unrelated to the referral disorder, although only 4 were ultimately considered reportable. Our results demonstrate the value of genome sequencing for routine clinical diagnosis but also highlight many outstanding challenges.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Diagnóstico Molecular / Sequenciamento de Nucleotídeos em Larga Escala / Doenças Genéticas Inatas Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Técnicas de Diagnóstico Molecular / Sequenciamento de Nucleotídeos em Larga Escala / Doenças Genéticas Inatas Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Reino Unido